Results: All pairwise differences were accompanied by wide confidence intervals, and none of the adjuncts were statistically significantly superior to another. Local doxycycline hyclate and photodynamic therapy with a diode laser had the highest probabilities for ranking first and second, respectively. Publication bias was evident, with fewer than expected studies with small effects. The lack of these studies inflated the treatment effects by an estimated by 20%.
| BACKGROUND
The American Dental Association published "Evidence-Based Clinical Practice Guideline on the Nonsurgical Treatment of Chronic Periodontitis by Scaling and Root Planing with or without Adjuncts" (Smiley et al., 2015a,b) , heretofore referred to as the "Guideline." This Guideline is an evidence-based approach to the provision of care for chronic periodontitis patients.
While the Guideline provides recommendations regarding the use of various adjuncts to scaling and root planing (SRP), it does not compare the adjuncts to each other. However, many patients and dental practitioners face this exact question: Which is the best treatment among the adjuncts? A network meta-analysis (NMA) is a method to build on findings from a conventional meta-analysis.
Whereas a typical meta-analysis compares two treatments in a particular population, the NMA compares more than two treatments, ideally all relevant treatment alternatives. Consequently, network meta-analyses have been recommended as the highest level of evidence for treatment guidelines (Leucht et al., 2016) . Therefore, comparing the nine adjunct treatments included in the Guideline to each other in a NMA can generate clinically meaningful comparative efficacy data.
In this study, we aimed to provide comparative treatment effect estimates for non-surgical treatments of chronic periodontitis based on scaling and root planing with adjuncts utilizing an NMA of studies that were included in the recent Guideline.
| MATERIALS AND METHODS

| Studies
To develop the Guidelines, potentially relevant articles from two electronic databases and selected systematic reviews were reviewed independently and in duplicate by multiple ADA panellists following a two-phase approach according to PRISMA guidelines (for additional information on the search strategy, see Smiley et al. (2015a,b) . Change in clinical attachment level (CAL) was considered as the primary outcome measure. Only randomized controlled trials if they were published after 1960 through July 2014, written in English and reported changes in CAL at least 6 months after randomization were included. Both parallel-arm and split-mouth studies were included, but studies of aggressive periodontitis were excluded. Experimental adjuncts, adjuncts not currently available in the United States, non-prescription (over-the-counter) adjuncts, adjuncts administered more than one week after SRP and adjuncts reapplied to progressing (worsening) tooth sites were also excluded.
Of the original 72 studies included in the Guideline, we excluded 11 that compared SRP against an untreated control group. The remaining 61 randomized clinical trials contained 74 pairwise comparisons between SRP plus an adjunct versus SRP alone (i.e. some trials contained multiple treatment arms that were considered separately in the original Guideline document (Smiley et al., 2015a,b) ). Studies other than trials included in the Guideline were not considered in this NMA because of a conceptual reason: We intended to make our NMA results complementary to the Guideline findings using the same primary studies.
"Adjuncts" were defined in this article as a nonsurgical periodontitis treatment in addition to SRP and including systemic antimicrobials, systemic sub-antimicrobial dose doxycycline (SDD), locally applied antimicrobials (chlorhexidine chips, doxycycline hyclate gel and minocycline microspheres) and non-surgical use of lasers (diode, both photodynamic and non-photodynamic therapies; Nd:YAG; and erbium).
| Investigation of several treatment groupings representing different effects
The Guideline investigated nine adjuncts:
systemic host modulation (SDD)
systemic antimicrobials (ANTI)
chlorhexidine chips (CHX)
doxycycline hyclate gel (DH)
minocycline microspheres (MM)
6. photodynamic therapy [PDT] with a diode laser (PDT)
diode laser [non-PDT] (DL)
Nd:YAG lasers (NDL)
Erbium lasers (ERL)
Studies were investigated in a star-shaped (Figure 1 ) NMA using the published data of the Guideline project (Smiley et al., 2015a,b) .
Here, nine adjuncts (plus SRP) were compared to a common comparator (SRP alone). Because these nine interventions are all connected in the network (i.e. each pair has a path from one to the other), 9*8/2 = 36 indirect comparisons can be performed among the nine interventions. The NMA was performed in a frequentist framework. Although the Guideline panel considered nine adjuncts, we further grouped them based on similarities in treatment approaches. This allowed us to provide an evolving picture of how treatment effects change when progressively more treatments are combined until all are considered together. The following groupings were investigated:
1. Nine groups suggested by the expert panel of the Guideline.
This categorization represents a grouping based on clinical application of the treatments.
2.
Four groups based on the mechanism of action: 1. host-modulating agents; 2. systemic antimicrobials; 3. topical antimicrobials (chlorhexidine chips, DH gel, MM, PDT with a DL); and 4. lasers (DL [non-PDT], Nd: YAG lasers, ERL).
3.
Three groups based on a more general mechanism of action:
1. host-modulating agents; 2. topical and systemic antimicrobials; and 3. lasers.
4.
Two groups based on an even more general mechanism of action:
we combined all antibiotics, antimicrobials and host-modulating agents versus all laser treatments together.
5.
All treatments combined, representing the non-specific treatment effect of adjuncts in general compared to SRP alone.
Clinical Relevance
Scientific rationale for the study: Various adjuncts are recommended for use in conjunction with SRP. The comparison of these adjuncts to each other using a systematic framework can yield vital information on their effectiveness to inform clinical decision-making. 
| Data analysis
We first calculated treatment effects for the nine adjuncts (compared to SRP) based on the NMA and compared them to the treatment effects of the Guideline project. We anticipated that NMA treatment effects should be very similar to Guideline meta-analysis results because computations would only use different variance estimators to derive the summary estimates. We performed pairwise comparisons of treatments and computed, for each of the five groupings above, a CAL difference and 95% confidence intervals. Based on the 9*8/2 = 36 treatment effects for the nine groups, that is grouping 1, we also ranked the interventions. In our frequentist approach to NMA (Lu & Ades, 2004; Salanti, Higgins, Ades & Ioannidis, 2008; White, 2011), we used a parametric bootstrap procedure using 50,000 repetitions to allow for parameter uncertainty (White, Barrett, Jackson & Higgins, 2012) . Ranking probabilities are presented in a cumulative bar chart, showing the probability that each of the nine treatments rank first, second, third and so on out of all nine interventions compared. We also calculated the Surface Under the Cumulative RAnking (SUCRA) curve.
SUCRA estimates the area under the curve underneath a cumulative ranking line starting with rank 1. Therefore, higher probabilities for better treatment ranks would result in a steeper ranking line and, hence, a large area under the ranking line. Larger SUCRA values represent better treatments on a scale from 0 to 1. SUCRA is a transformation of the mean rank of treatments, taking into account magnitude and variability of all relative treatment effects (Salanti, Ades & Ioannidis, 2011) .
After comparing all nine treatments with each other (grouping 1), we derived treatment effects (CAL differences) and their 95% confidence intervals for groupings 2-5 (see above) with the intent to study whether larger groups of related treatments had different effects. Our approach was to combine treatments unless clinically relevant and statistically significant effects emerge that prohibit further combination.
We also investigated statistical heterogeneity when the number of studies was sufficiently large. The Cochrane Collaboration (Higgins & Green, 2011) suggests that an I 2 value of 0% to 40% represents heterogeneity that might not be important. I 2 values of 30%-60% may represent moderate heterogeneity, 50%-90% substantial heterogeneity and 75%-100% considerable heterogeneity. We expected to find a moderate level of heterogeneity (I 2 of 60% or less) because of variations in baseline disease extent and severity among the studies, and because they were conducted over three decades and in 20 countries on five continents.
We also investigated whether publication bias exists. We used a contour-enhanced funnel plot (Palmer, Peters, Sutton & Moreno, 2008) to visually assess bias. Here, contours of statistical significance are overlaid on the funnel plot, presenting information whether studies appear missing in areas of low statistical significance. This situation would indicate that funnel asymmetry is likely due to publication bias.
If bias appears to be present, as a next step, the missing studies could be imputed creating an unbiased data set. Then, the meta-analysis would be performed again, taking the apparently missing studies into account. The "trim-and-fill" method accomplishes this (Duval & Tweedie, 2000) . For statistical assessment of funnel plot asymmetry, we also performed Egger's test (a test for the Y intercept = 0 from a linear regression of normalized effect estimate against effect precision; Egger, Davey Smith, Schneider & Minder, 1997).
We used the statistical software Stata (version 14; StataCorp, College Station, TX, USA) and user-written network meta-analyses programs including mvmeta (White, 2011) and network graphs (Chaimani, Higgins, Mavridis, Spyridonos & Salanti, 2013; Chaimani & Salanti, 2015) .
| RESULTS
| Comparison between NMA-based treatment effects and Guideline-presented treatment effects for nine adjuncts
Comparing the adjuncts' estimates from the NMA (74 studies simultaneously analyzed) with those derived from the original random-effects F I G U R E 1 Network plot of 74 studies in nine adjuncts (plus SRP) versus a common comparator SRP alone included in the Guideline Project (nodes and edges weighed according to the number of studies involved in each comparison of nine adjuncts versus SRP alone). SRP, scaling and root planing model (74 studies analyzed in the nine adjuncts groups (Smiley et al., 2015a,b) ) showed small differences (≤0.09 mm CAL) and indicated that both meta-analytic approaches provided similar results when applied to the same research question.
| Pairwise comparisons across nine adjuncts
The 36 pairwise treatment differences varied in absolute size from 0.01 to 0.43 mm CAL. All differences were accompanied by wide confidence intervals, and none of the adjuncts were statistically significantly superior to another. These pairwise differences between adjuncts corresponded to differences between 0.20 and 0.64 mm for adjuncts versus SRP alone. These latter treatment effects were larger because SRP is less effective than the same treatment plus an adjunct.
Five of the nine differences were statistically significant.
| Treatment ranking
Doxycycline hyclate gel was ranked the best treatment by the NMA.
It had the largest effect of 0.64 mm CAL compared to SRP alone (Table 1) . It had a probability of 45% of being the best treatment, 15% of being the second, and 10% of being the third best treatment for PDT with a DL. The cumulative probability of being ranked in the top 3 was similar for both adjuncts (70% for DH and 68% for PDT).
The SUCRA values yielded similar rankings. These values were largest for DH (78.5%) and PDT (78%) (Figure 2 , right panel). The third highest SUCRA value was 61% for the systemic host modulator (SDD).
Thus, both DH and PDT were top-ranked adjuncts using each of the two statistical ranking methods.
When all possible differences between 4, 3 and 2 treatment groups were analyzed, differences decreased. The largest differences were 0.18 mm CAL for the four groups and 0.14 mm CAL for three groups. The two groups (all laser treatments versus all other treatments) showed a difference of 0.12 (−0.19 to 0.44) mm CAL. All these differences were judged to be clinically insignificant based on the Guidelines' judgment that 0.0-0.2 represents a "zero effect." While confidence intervals became narrower, none of the differences became statistically significant, that is, regardless of whether adjuncts were analyzed as individual treatments or as groups of related treatments effects were absent. We interpreted these findings as evidence against substantial differences across treatments and as rationale to combine all adjuncts into a single group.
Combining all 74 studies considers the effect of a "global" adjunct (plus SRP) group versus SRP alone. The summary estimate was 0.35 (95% CI: 0.30-0.40) in a fixed-effects model and 0.38 (95% CI: 0.28-0.48) mm in a random-effects model. In the latter model, the standard deviation of the true effects was 0.33 mm CAL and the I 2 was 70%, representing "substantial" heterogeneity.
To identify sources of heterogeneity, we searched for outlier studies, that is, studies that, when deleted, would decrease heterogeneity substantially. Deleting two studies (Pradeep and Ginanelli) reduced the I 2 to 49%, representing only "moderate" heterogeneity. Excluding these two studies, the summary estimates were reduced to 0.28 mm (95% CI: 0.23-0.33) in the fixed-effects model and 0.32 mm (95% CI:
0.24-0.40) in the random-effects model. In the latter model, the summary estimate was reduced in absolute terms by 0.06 mm CAL and in relative terms by 15% after excluding the two outlying studies.
| Publication bias
The magnitude of publication bias for all adjuncts combined (excluding Pradeep and Ginanelli to achieve moderate heterogeneity) is depicted in the funnel plot (Figure 3) . Overall, there were fewer than expected small studies with negative effects (p value for Egger's test for small study effects = .01). Following imputation of "missing" small studies using a trim-and-fill analysis, the overall treatment effects from the 
| DISCUSSION
This meta-analysis led to three major findings: (1) adjuncts to SRP improved the response to SRP, measured by CAL gains, by about a third of a mm over 6-12 months; (2) there were no significant differences in CAL gains and acceptable study heterogeneity (after the two most influential studies were deleted) across the nine adjuncts evaluated in the recent ADA non-surgical periodontal therapy guidelines paper, suggesting that effects on CAL across disparate adjuncts may be similar; and (3) there was evidence for publication bias in the related literature. The magnitude of this bias is not trivial and has the potential to affect clinical decision-making because the "corrected" overall treatment effect is about 20% smaller than the average effect reported in the literature.
Our first main finding is the magnitude of the overall effect of 0.32 mm CAL for adjuncts. How can the magnitude be interpreted?
First, considering the effect in its original metric "mm," the magnitude can be compared with the SRP effect alone. The adjuncts' effect is about a third smaller than the effect of SRP alone, which was 0.49 mm (Smiley et al., 2015a,b) . Based on the expert-opinion, clinical relevance scale for interpreting mean differences in CAL (Smiley et al., 2015a,b) , Significantly better than SRP in conventional meta-analysis.
treatment effect in a relative metric of its magnitude to its variability, an effect size (defined as mean effect divided by standard deviation of the effect) can be calculated that can be compared to guidelines.
This standardized effect size was 0.92, which means the effect is almost as large as the standard deviation of that effect. According to commonly applied guidelines from Cohen, an effect size >0.8 is considered a "large" effect (Cohen, 1998) . Although the adjunct effect is statistically significant, its magnitude might have been substantially underestimated due to the use of whole-mouth measurements by the majority of the included studies. As SRP alone benefits the majority Pain, Orofacial Appearance and Psychosocial Impact -core areas where patients perceive oral conditions' and dental interventions' impact-should be improved by adjuncts, in particular through prevention of tooth loss.
CAL is related to OHRQoL; for example, CAL ≥ 4 mm (% of sites) was correlated with r = .34 (Eltas, Uslu & Eltas, 2016) to the summary score of OHIP-14 (Slade, 1997) , a widely used OHRQoL instrument.
CAL is predictive of tooth loss as well as denture status. OHRQoL was also substantially correlated with tooth loss (Gerritsen, Allen, Witter, Bronkhorst & Creugers, 2010) and was associated with denture status (John et al., 2004) . Therefore, the expected patient-perceived treatment effect from adjuncts should not be trivial even if considerable uncertainty about the actual magnitude of the impact exists. In previous studies, periodontitis had a substantial effect on OHRQoL (Durham et al., 2013) and treatment studies showed an OHRQoL improvement over shorter time periods (Shanbhag, Dahiya & Croucher, 2012) , but is currently not well understood over a longer time. From a methodological perspective, use of patient-oriented outcomes in general and OHRQoL assessment in particular are strongly encouraged to complement traditional disease-oriented outcomes to more completely understand a treatment impact. In particular, future randomized trials evaluating effects of periodontal treatments in general and adjuncts specifically should include OHRQoL measures. Clinically feasible and widely comparable instruments ranging from 5 (Naik, John, Kohli, Self & Flynn, 2016) over 14 (Slade, 1997) to 49 (Slade & Spencer, 1994 ) items exist, providing pragmatic options to measure the patientperceived impact with the desired level of precision.
Our second main finding is the homogeneity of the included trials. When we excluded the two most influential studies on the metaanalysis, the remaining 72 studies reached an acceptable level of heterogeneity considering their clinical and methodological diversity; (Higgins & Green, 2011 ) that is, they represented a level of variability that is compatible with an underlying common effect with acceptable variability so that treatment can be summarized in an overall effect.
Support for small differences across studies came from our pairwise comparisons of individual treatment and treatment groupings. Also, our definition of the "best treatment"-one of the major goals of a NMA-needs some interpretation. It is based on NMA-derived probabilities of treatment rankings. Our results indicated that DH gel had, with 45%, the highest probability to be the best treatment as compared to PDT with a DL with only a 20% probability. This is a notable difference. However, when all treatment rankings (best, second, third, etc.) were incorporated in the analysis, PDT with a DL had a similar overall treatment ranking compared with DH gel, and therefore, we considered both adjuncts as the best treatments. a Guideline meta-analysis did not provide an estimate for these groupings.
T A B L E 3 Pairwise comparisons (N = 3) of three groups of adjuvant periodontal treatments (largest difference in bold) included in the Guideline Project and summary estimates for the treatments + SRP versus SRP alone F I G U R E 3 Contour-enhanced funnel plot of the 72 studies (all studies of the Guidelines shown, but without Pradeep and Ginanelli to achieve moderate heterogeneity), plotting each study's clinical attachment level effect versus its standard error as well as "trim-andfill" imputed studies
The findings of relative homogeneous treatment effects have theoretical and practical implications. The former point to common mechanisms, that is, nonspecific effects such as oral health changes due to trial participation or specific effects due to commonalities among adjuncts. The latter point of smaller effect differences among the treatments provides patients and dentists with a better and sim-
pler understanding of what they can expect from adjuncts and, in the absence of substantial CAL gain differences across treatments, puts more emphasis on the profile of other treatment characteristics for clinical decision-making.
Finally, when interpreting the magnitude of the effects, the precision of the estimates must be considered. Our meta-analysis included a large number of studies, more than most network meta-analyses in oral health. Nevertheless, even with 72 studies the precision of our estimates is mediocre. Lower limits of confidence intervals translate into medium or even small effect sizes.
Our third main finding is of methodological nature: We found evidence for publication bias. Healthcare providers, patients and policy makers will receive misleading information; that is, the information is not as robust as they think. Publication bias per se is not a problem.
Bias of trivial magnitude, that is, bias that does not lead to relevant impact, is not a challenge even if the bias is statistically significant. In contrast, bias of non-trivial size can lead to a change in decision-making. In our study, we found evidence for a clinically relevant publication bias effect because the treatment effect may not be "large" anymore and the patient-perceived impact considerably lower.
While the presence of publication bias presents a methodological challenge to systematic reviews/meta-analyses, it also offers a potential for more insight into treatment mechanisms. On the one hand, specific types of selection bias, poor methodological quality, sampling variation and chance can cause publication bias. On the other hand, true heterogeneity among studies, that is, the size of the effect differs according to study size; for example, differences in the treated disease population or in the interventions applied in smaller studies, can also cause "small study effects" (Egger et al., 1997) . In the latter case, such small study effects would be informative because they point to clinically interesting differences among patient populations. These effects should be explored further because of true differences in the effect of treatment in specific populations and/or specific interventions.
| Strengths and limitations
We used available data for the NMA. The design of the Guideline project led to a star-shaped network presented here because all adjuncts were compared to SRP. Some original randomized clinical trials included in the Guideline had more than two arms with two or more of the nine investigated treatments. These data could have been incorporated in the present study and would have led to a more informative NMA.
However, the number of the not used, but available evidence was small because only one study would contain a direct comparison among the nine groups of adjuncts. Likely, results of treatment ranking and existence of publication bias would not have changed much in the data set of 74 studies if this additional evidence would have been incorporated.
More importantly than this technical aspect, we chose not to include these studies for a conceptual reason: We intended to make our findings complementary to the Guideline using the identical data.
Our NMA-based effect estimates for the pairwise adjuncts comparisons could have been derived with a simpler approach. In a star-shaped NMA design (and under certain assumptions), the difference (d) between a treatment B and a treatment C (dBC) would be dBC = dAC -dAB when both treatments B and C are compared to the common comparator A (dAC as well as dAB are their individual treatment difference with the comparator) (Jansen et al., 2011) . This simple calculation of treatment effects illustrates the principles of deriving treatment effects in an NMA.
Like traditional meta-analyses, NMA also relies on the independence of data, that is, that a particular study is not more informative about one study than another. Violations of the independence assumption occurred in the NMA, for example, when smokers and non-smokers from a particular trial or when partial-and full-mouth recordings were both included as separate studies. Furthermore, some studies had more than two treatment arms and the individual comparisons were sometimes included in a particular adjunct group. As mentioned before, to be comparable, we analyzed the identical data set as the Guideline project, but violations of the independence assumption would lead to slightly larger uncertainty around the effect estimates compared to what we reported.
We would like to emphasize that we deleted or combined different adjuncts purely based on statistical reasons. Our general approach was that we wanted to aggregate studies when there was no compelling reason not to do so. While authors of the Guideline grouped treatments according to clinical expertise, we started in this study with this grouping and then synthesized more and more studies because differences between groupings seemed not of substantial magnitude and could not be differentiated from chance. However, we emphasize that the pattern of findings-that individual adjuncts and groups of adjuncts showed consistently trivial differences among them-is a convincing argument for our analytic strategy that was performed in a reasonably large sample size (for a meta-analysis).
| CONCLUSIONS
We interpret the summary estimate as the typical effect patients can expect when another treatment is added to the standard SRP.
Our NMA of adjuncts, that is, treatments in addition to SRP, provided complementary information to the "Evidence-Based Clinical Practice
Guideline on the Nonsurgical Treatment of Chronic Periodontitis by Scaling and Root Planing with or without Adjuncts." Our finding that adjuncts typically provide a third of a mm or a quarter (when publication bias is considered) of a mm CAL gain of 6-12 months for patients with chronic periodontitis is a contribution to our understanding of mechanisms of periodontal treatment in general and a practical information for patients and health care providers. It further strengthens the recommendation that SRP is considered the primary therapeutic modality for non-surgical periodontal therapy. Further research is required to identify population subgroups that benefit from adjuncts.
Our finding of publication bias for adjuncts is relevant for the periodontal treatment literature in general. If the phenomenon exists for such an important and widely studied intervention, it is likely that it is also present for other treatments as well, but it often remains undetected because of the usually small number of included primary studies.
We believe that the effect we identified in this study can be interpreted as what adjuncts have in common, that is, the non-specific treatment effects from adding another treatment to address attachment loss due to chronic periodontitis. The patient-perceived benefit due to this gain is not clear because CAL is a physical indicator of periodontal health, a disease-oriented outcome.
